Advertisement

Drugs

, Volume 77, Issue 1, pp 75–83 | Cite as

Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections

  • Karly P. Garnock-JonesEmail author
Adis Drug Evaluation

Abstract

Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin and its clinical efficacy and tolerability as a single-dose regimen in the treatment of adult patients with ABSSSI. Single-dose dalbavancin is an effective and generally well tolerated treatment option for adults with ABSSSI, with noninferior efficacy to the two-dose dalbavancin regimen with regard to early clinical response (at 48–72 h) and low rates of adverse events. Clinical success rates at days 14 and 28 also did not significantly differ between the single- and two-dose dalbavancin regimens; neither did clinical success rates at day 14 when analysed by baseline pathogen. It has a broad spectrum of activity against common ABSSSI-related pathogens, and a favourable pharmacokinetic profile allowing for the convenience of single-dose administration. Thus, dalbavancin presents a promising alternative to conventional antibacterials for the treatment of ABSSSI in adult patients.

Keywords

Vancomycin Linezolid Daptomycin Clinical Success Rate Moderate Renal Impairment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

During the peer review process, the manufacturer of dalbavancin was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Karly P. Garnock-Jones is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Juul JJ, Mullins CF, Peppard WJ, et al. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin. Ther Clin Risk Manag. 2016;12:225–32.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Leuthner KD, Buechler KA, Kogan D, et al. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931–40.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Van Bambeke F. Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review. Drugs. 2015;75(18):2073–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Durata Therapeutics US Ltd. Dalvance® (dalbavancin for injection, for intravenous use): US prescribing information. 2016. http://www.allergan.com. Accessed 11 Nov 2016.
  5. 5.
    European Medicines Agency. Xydalba® (dalbavancin powder for concentrate for solution for infusion): EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 11 Nov 2016.
  6. 6.
    Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–79.CrossRefPubMedGoogle Scholar
  7. 7.
    Scott LJ. Dalbavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75(11):1281–91.CrossRefPubMedGoogle Scholar
  8. 8.
    Anderson VR, Keating GM. Dalbavancin. Drugs. 2008;68(5):639–48.CrossRefPubMedGoogle Scholar
  9. 9.
    Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859–86.CrossRefPubMedGoogle Scholar
  10. 10.
    The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. 2016. http://www.eucast.org/clinical_breakpoints/. Accessed 11 Nov 2016.
  11. 11.
    Lin G, Credito K, Ednie LM, et al. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother. 2005;49(2):770–2.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lopez S, Hackbarth C, Romano G, et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother. 2005;55(Suppl 2):ii21–4.Google Scholar
  13. 13.
    Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(3):940–5.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Streit JM, Fritsche TR, Sader HS, et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 2004;48(2):137–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Biedenbach DJ, Bell JM, Sader HS, et al. Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates. Antimicrob Agents Chemother. 2009;53(3):1260–3.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Jones RN, Farrell DJ, Flamm RK, et al. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis. 2015;82(1):73–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75(3):304–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Jones RN, Flamm RK, Sader HS. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis. 2013;76(1):122–3.CrossRefPubMedGoogle Scholar
  19. 19.
    Karlowsky JA, Adam HJ, Poutanen SM, et al. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007–2009 study. Diagn Microbiol Infect Dis. 2011;69(3):342–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Huband MD, Castanheira M, Farrell DJ, et al. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011–2013). Int J Antimicrob Agents. 2016;47(6):495–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Mendes RE, Castanheira M, Farrell DJ, et al. Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13). J Antimicrob Chemother. 2016;71(1):276–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Dunne M, Boucher H, Wilcox MH, et al. Microbiologic analysis of target pathogens identified in the dalbavancin DISCOVER program [abstract no. 1338]. In: Infectious Diseases Week. 2013.Google Scholar
  24. 24.
    Klinker KP, Borgert SJ. Beyond vancomycin: the tail of the lipoglycopeptides. Clin Ther. 2015;37(12):2619–36.CrossRefPubMedGoogle Scholar
  25. 25.
    Johnson DM, Fritsche TR, Sader HS, et al. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents. 2006;27(6):557–60.CrossRefPubMedGoogle Scholar
  26. 26.
    Koeth LM, DiFranco-Fisher JM, Dunne M, et al. Dalbavancin and azithromycin synergy/antagonism study by checkerboard MIC [abstract no. D-877]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.Google Scholar
  27. 27.
    Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51(5):1633–42.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicob Chemother. 2006;58(4):802–5.CrossRefGoogle Scholar
  29. 29.
    Bhavnani SM, Hammel JP, Rubino CM, et al. Pharmacokinetic–pharmacodynamic (PK–PD) analyses for the efficacy of dalbavancin (DAL) using phase 3 data from patients with acute bacterial skin and skin structure infections (ABSSSI) [abstract no. A-1186]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.Google Scholar
  30. 30.
    Dunne MW, Zhou M, Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2015;45(4):393–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicob Chemother. 2007;60(3):681–4.CrossRefGoogle Scholar
  32. 32.
    Scoble PJ, Owens RC Jr, Puttagunta S. Pharmacokinetics, safety, and tolerability of a single 500-mg or 1000-mg intravenous dose of dalbavancin in healthy Japanese subjects. Clin Drug Investig. 2015;35(12):785–93.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Data on file, Allergan, 2015.Google Scholar
  34. 34.
    Tran MC, Naumovski S, Goldstein EJ. The times they are a-changin’: new antibacterials for skin and skin structure infections. Am J Clin Dermatol. 2015;16(3):137–46.CrossRefPubMedGoogle Scholar
  35. 35.
    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–52.CrossRefPubMedGoogle Scholar
  36. 36.
    Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.CrossRefPubMedGoogle Scholar
  37. 37.
    The Medicines Company. Orbactiv® (oritavancin for injection, for intravenous use): US prescribing information. 2016. http://www.themedicinescompany.com. Accessed 29 Aug 2016.
  38. 38.
    European Medicines Agency. Orbactiv® (oritavancin 400 mg powder for concentrate for solution for infusion): EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 29 Aug 2016.
  39. 39.
    European Medicines Agency. EMA assessment report for Xydalba® (dalbavancin powder for concentrate for solution for infusion). EMA/39820/2015. 2015. http://www.ema.europa.eu. Accessed 2 Nov 2016.
  40. 40.
    Syed YY, Scott LJ. Oritavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75(16):1891–902.CrossRefPubMedGoogle Scholar
  41. 41.
    Everson-Stewart S, Emerson SS. Bio-creep in non-inferiority clinical trials. Stat Med. 2010;29(27):2769–80.CrossRefPubMedGoogle Scholar
  42. 42.
    Pollack CV Jr, Amin A, Ford WT Jr, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48(4):508–19.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations